Skip to main content

Advertisement

Table 2 Treatment characteristics

From: Decrease in bone mineral density during three months after diagnosis of early rheumatoid arthritis measured by digital X-ray radiogrammetry predicts radiographic joint damage after one year

Treatment Number (percentage) of patients
csDMARDs/biologics started at baseline, n (%) 152 (91.0)
 - MTX, n (%) 147 (88.0)
 - Other csDMARDs, n (%) 4 (2.4)
 - csDMARD triple therapy, n (%) 1 (0.6)
Anti-TNF at baseline, n (%) 1 (0.6)
Anti-TNF ever, n (%) 18 (10.8)
Other bDMARDs 6 (3.6)
Oral glucocorticoids, n (%) 138 (82.6)
Calcium supplements, n (%)a 79 (49.1)
Bisphosphonates, n (%)b 7 (6.0)
  1. Abbreviations: MTX methotrexte, cDMARDs conventional disease modifying anti-rheumatic drugs, TNF tumor necrosis factor, bDMARDs biologic disease modifying anti-rheumatic drugs
  2. aData available for 161 patients
  3. bData available for 124 patients